Journal of Animal Health and Production

Review Article
J. Anim. Health Prod. 9(s1): 1-8
View Full HTML
Download PDF

Sawsan Mohamed El-Sheikh, Nagah Edrees, Hend El-Sayed*, Naglaa Zakria Eleiwa

Department of Pharmacology, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Egypt.

Abstract | Cisplatin is a potent, first-line chemotherapeutic drug used for a variety of solid tumors in pet animals as well as humans. The therapeutic application of cisplatin is restricted due to its resistance and toxicity to the healthy tissues. In addition, it exhibits less selectivity for tumor against normal tissue that may be a crucial limiting element for its worth. To handle these limitations of the free drug, nanotechnology-based therapeutics have shown clear benefits compared to unmodified drugs, including better half-life, survival, performance targeting and less side effects for patients. Nanoparticle drug delivery systems have been investigated to facilitate the delivery of cisplatin to kill cancer cells. Nanoparticles/drug conjugate design has important effects on pharmacokinetics, bio-distribution of the drug which reduces its observed toxicity. Formulations that allow enhanced delivery and controlled release of anti-tumor drug can actually accomplish the goal of nanomedicine as a means of enhancing effectiveness and minimal serious side effects. Here, we survey some of the most common adverse effects associated with cisplatin conventional therapy with highlights latest progress in formulations of nanoparticles; concentrating on the promising agents in preclinical or clinical studies; as smart nanocarriers conjugate that composed of metal nanoparticles as a delivery vehicle for cisplatin to target the tumor mass and reduce its side effects and tissue toxicity.

Keywords | Cisplatin, Drug Conjugate, Nanotechnology, Side effects, Silver nanoparticles